The New York Times recently reported that many trans patients ‘do not fully rebound’ from the health impacts of puberty blockers. “There’s going to be a price,” said Dr. Sundeep Khosla, who leads a bone research lab at the Mayo Clinic. “And the price is probably going to be some deficit in skeletal mass.”